C-reactive protein as a marker for acute coronary syndromes

Mach, François; Lovis, Christian; Gaspoz, Jean‐Michel; Unger, Pierre-François; Bouillie, M.; Urban, Philippe; Rutishauser, W

doi:10.1093/oxfordjournals.eurheartj.a015198

Cited by 46 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most of the patients, CRP levels in serum rise after 12 hours of symptom onset (16), so it can be assumed that levels on admission reflect baseline inflammation. This study shows, in accordance with earlier studies (3,17), that patients with ACS have higher levels of CRP than control subjects, and also, that UA patients have significantly higher levels of CRP (7.28 mg/L) than AMI patients (4.10 mg/L). It should be noted that in patients with UA time from symptom onset to admission was longer and not reported as precisely as in patients with AMI.…”

Section: Discussionsupporting

confidence: 93%

C-Reactive Protein in Estimating Inflammatory Status in Patients with Acute Coronary Syndrome

Dimitrijevic¹,

Đorić-Stojčevski²,

Ignjatović³

et al. 2008

Journal of Medical Biochemistry

View full text Add to dashboard Cite

C-Reactive Protein in Estimating Inflammatory Status in Patients with Acute Coronary Syndrome Chronic inflammation plays a key role in the pathogenesis of atherosclerosis, and is considered as a risk factor for the occurrence of acute coronary events, together with traditional risk factors such as age, smoking, hypercholesterolemia, diabetes mellitus and genetic predisposition. In this study, inflammatory status was estimated in patients with acute coronary syndrome. C-reactive protein, erythrocyte sedimentation rate and white blood cell count were measured at admission to the hospital in 25 patients with unstable angina pectoris and 31 patients with acute myocardial infarction, and compared with healthy control group (n = 59). C-reactive protein was the only parameter that differed significantly between all three groups (p < 0.0001), and patients with unstable angina had higher levels (median 7.28 mg/L) than patients with myocardial infarction (4.10 mg/L) and control group (1.07 mg/L). The obtained results show that levels of chronic inflammation in patients with acute coronary syndrome are significantly higher than baseline inflammation levels in a healthy population.

show abstract

Section: Discussionsupporting

confidence: 93%

C-Reactive Protein in Estimating Inflammatory Status in Patients with Acute Coronary Syndrome

Dimitrijevic¹,

Đorić-Stojčevski²,

Ignjatović³

et al. 2008

Journal of Medical Biochemistry

View full text Add to dashboard Cite

show abstract

“…Diagnostic sensitivity and specificity appear to be superior to those of hs-CRP, thus, indicating that sSR-PSOX/CXCL16 is a useful biomarker for detecting ACS, alone or in combination with other biomarkers, including TnT 19) , sLOX-1 7) , and hs-CRP 18) . In addition, circulating sSR-PSOX/CXCL16 may also be useful for risk stratification and estimation of the prognosis of ACS or stable coronary artery disease patients, as well as the long-term future risk for cardiovascular events in healthy subjects, as previously shown in hs-CRP 21,22) .…”

Section: Discussionmentioning

confidence: 99%

“…In the present study, therefore, we explored circulating levels of sSR-PSOX/CXCL16 in ACS, comparing the results with those of a proinflammatory marker high-sensitivity C-reactive protein (hs-CRP) and a cardiac injury marker troponin T (TnT), and further evaluated its potential value as a diagnostic biomarker for ACS 7,18,19) .…”

Section: Introductionmentioning

confidence: 99%

Circulating Soluble SR-PSOX/CXCL16 as a Biomarker for Acute Coronary Syndrome -Comparison with High-Sensitivity C-Reactive Protein

Mitsuoka¹,

Toyohara²,

Kume³

et al. 2009

JAT

View full text Add to dashboard Cite

Aim: Diagnostic values of soluble SR-PSOX/CXCL16 (sSR-PSOX/CXCL16), a receptor for atherogenic oxidized LDL and a membrane-anchored chemokine for CXCR6-positive lymphocytes, for acute coronary syndrome (ACS) were evaluated. Methods: We examined 106 patients undergoing coronary angiography (CAG); 17 patients with ACS and 89 patients without ACS (non-ACS) including stable angina. Circulating sSR-SPOX/CXCL16 was measured in peripheral venous blood by sandwich ELISA. Results: Age, gender, prevalence of diabetes or hypertension, and serum lipid profiles were not significantly different between ACS and non-ACS. Presence or absence of risk factors, such as diabetes, smoking and hypertension, did not significantly affect circulating sSR-PSOX/CXCL16 levels. Circulating sSR-PSOX/CXCL16 levels were significantly lower in ACS than non-ACS (median: 3.05 versus 3.36 ng/mL, p 0.02). Lipid profiles, high-sensitivity C-reactive protein (hs-CRP), cardiac troponin T (TnT), and soluble LOX-1 (sLOX-1) showed no significant correlation with sSR-PSOX/ CXCL16. Receiver-operating characteristic (ROC) curves for ACS detection indicate higher sensitivity and specificity for sSR-PSOX/CXCL16 than hs-CRP. In the TnT-negative and sLOX-1-negative subpopulation, sSR-PSOX/CXCL16 showed similar sensitivity and specificity for ACS; however, hs-CRP showed less sensitivity and specificity for ACS when compared with the whole population. Conclusion: sSR-PSOX/CXCL16 is a biomarker for ACS, which would provide additional diagnostic information besides TnT and sLOX-1. J Atheroscler

show abstract

“…Mach et al 14 reported that C-reactive protein levels measured on hospital admission in patients suspected of having ischemic heart disease may be a marker of acute coronary syndromes and may be very useful in identifying patients at high risk for developing myocardial infarction.…”

Section: Discussionmentioning

confidence: 99%